5 dead, over 100 hospitalised from recalled Japanese health supplements

Kobayashi Pharmaceutical Co. came under fire for not going public quickly with problems known internally as early as January

drugs, medical, medicine
AP
2 min read Last Updated : Mar 29 2024 | 6:03 PM IST
Five people who took a Japanese health supplement have died and more than 100 have been hospitalised as of Friday, a week after a pharmaceutical company issued a recall of the products.
 
Osaka-based Kobayashi Pharmaceutical Co. came under fire for not going public quickly with problems known internally as early as January. The first public announcement came March 22.
 
Earlier in the week, the number of deaths stood at two people. Company officials updated the number of dead to five Friday, and said 114 people were being treated in hospitals after taking products — including Benikoji Choleste Help meant to lower cholesterol — that contain an ingredient called benikoji, a red species of mold.
 
Some people developed kidney problems after taking the supplements, but the exact cause was still under investigation in cooperation with government laboratories, according to the manufacturer.
 
“We apologise deeply,” President Akihiro Kobayashi told reporters Friday, bowing for a long time to emphasise the apology alongside three other top company officials.
 
He expressed remorse to those who have died and have been sickened, and to their families. He also apologised for the troubles caused to the entire health food industry and the medical profession, adding that the company was working to prevent further damage and improve crisis management.
 
The company's products have been recalled — as have dozens of other products that contain benikoji, including miso paste, crackers and a vinegar dressing. Japan's health ministry put up a list on its official site of all the recalled products, including some that use benikoji for food coloring.
 
The ministry warned the deaths could keep growing. The supplements could be bought at drug stores without a prescription from a doctor, and some may have been purchased or exported before the recall, including by tourists who may not be aware of the health risks.
 
Kobayashi Pharmaceutical had been selling benikoji products for years, with a million packages sold over the past three fiscal years, but a problem crept up with the supplements produced in 2023. Kobayashi Pharmaceutical said it produced 18.5 tonnes of benikoji last year.
 
Some analysts blame the recent deregulation initiatives, which simplified and sped up approval for health products to spur economic growth.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :healthMedicinesdrugs

First Published: Mar 29 2024 | 6:03 PM IST

Next Story